All In Biotech

Drug Trial Radar · NCT07490262

A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.

A Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy as First-line Treatment in Previously Untreated Patients With Unresectable or Metastatic Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: Apr 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 680 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

680

Planned (sponsor's estimate)

Start

Mar 27, 2026

Primary completion

Dec 31, 2027

Study completion Dec 31, 2030

Sponsor

Sponsor type
Industry
First posted
Mar 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, controlled, open-label, multicenter, seamless Phase II/III trial designed to evaluate the efficacy and safety of the combination regimen of IBI310 and sintilimab in participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who are: (1) treatment-naive to systemic therapy; and (2) either unsuitable for curative-intent surgical resection or local therapy, or have experienced disease progression following prior surgical resection or local therapy.

Conditions

  • Hepatocellular Carcinoma (HCC)

Interventions

  • BevacizumabBiological

    15 mg/kg intravenous infusion, administered on Day 1 of each 3-week treatment cycle

  • CapecitabineDrug

    1000 mg/m² orally, administered on Days 1-14 of each 3-week treatment cycle, maximum 4 cycles.

  • OxaliplatinDrug

    85 mg/m² intravenous infusion, administered on Day 1 of each 3-week treatment cycle, maximum 4 cycles.

  • IBI310Biological

    1 mg/kg intravenous infusion, administered on Day 1 of each 6-week treatment cycle

  • SintilimabBiological

    200 mg intravenous infusion, administered on Day 1 of each 3-week treatment cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase II: ORR (Objective Response Rate) assessed by investigator per RECIST 1.1.Time frame: up to 2 years
  2. Phase II: PFS(Progression-Free Survival) assessed by investigator per RECIST 1.1.Time frame: up to 2 years
  3. Phase II: AEs(Adverse Event)Time frame: up to 2 years
  4. Phase II: TRAES(Treatment Emergent Adverse Event)Time frame: up to 2 years
  5. Phase II: SAEs(Serious Adverse Event)Time frame: up to 2 years
  6. Phase III: OS(Overall Survival)Time frame: up to 2 years
  7. Phase III: PFS(Progression-Free Survival)assessed by the Independent Radiologic Review Committee (IRRC) per RECIST 1.1.Time frame: up to 2 years

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hosptial of USTC

    Hefei, Anhui, China · Recruiting

  • Zhongshan Hospital, Fudan university

    Shanghai, Shanghai Municipality, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.